Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China

Stroke

Volumn 45, Issue 2, 2014, Pages 515-519

  Peng, Bin ^a   Ni, Jun ^a   Anderson, Craig S ^b   Zhu, Yicheng ^a   Wang, Yongjun ^c   Pu, Chuanqiang ^d   Wu, Jiang ^e   Wang, Jianming ^a   Zhou, Lixin ^a   Yao, Ming ^a   He, Jia ^f   Shan, Guangliang ^g   Gao, Shan ^a   Xu, Weihai ^a   Cui, Liying ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e JILIN UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Guideline; Patient compliance; Secondary prevention; Stroke

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CHINA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HOSPITAL DISCHARGE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STRUCTURED CARE PROGRAM;

GUIDELINE; PATIENT COMPLIANCE; SECONDARY PREVENTION; STROKE;

AGED; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CHINA; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; FEMALE; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SAMPLE SIZE; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 84893675642     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001424     Document Type: Article

References (17)

1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448-457.
2. Feigin VL. Stroke epidemiology in the developing world. Lancet. 2005;365:2160-2161.
3. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42:3651-3654.
4. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007;6:456-464.
5. Wang YJ, Zhang SM, Zhang L, Wang CX, Dong Q, Gao S, et al. Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2010. CNS Neurosci Ther. 2012;18:93-101.
6. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397-401.
7. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119:107-115.
8. Peng B, Zhu Y, Cui L, Ni J, Xu W, Zhou L, et al; SMART Study Group. Standard medical management in secondary prevention of ischemic stroke in China (SMART). Int J Stroke. 2011;6:461-465.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
10. Wei JW, Wang JG, Huang Y, Liu M, Wu Y, Wong LK, et al; ChinaQUEST Investigators. Secondary prevention of ischemic stroke in urban China. Stroke. 2010;41:967-974.
11. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, et al; Taiwan Stroke Registry Investigators. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation. 2010;122:1116-1123.
12. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/ american stroke association. Stroke. 2011;42:227-276.
13. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123.
14. Weimar C, Benemann J, Katsarava Z, Weber R, Diener HC. Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol. 2008;60:142-148.
15. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
16. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008;121:24-33.
17. China Internet Network Information Center. 25th statistical survey report on internet development in China. http://www.cnnic.net.cn/hlwfzyj/ hlwxzbg/hlwtjbg/201206/t20120612-26716.htm. Published January 15, 2010. Accessed October 12, 2011.